157 related articles for article (PubMed ID: 38162440)
1. Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report.
Yoshida T; Watanabe O; Nomura M; Yoshimoto Y; Maki Y; Takashima H
Front Neurol; 2023; 14():1322412. PubMed ID: 38162440
[TBL] [Abstract][Full Text] [Related]
2. Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder.
Nakashima S; Hao A; Uchio N; Matsumoto H
Cureus; 2024 Feb; 16(2):e55010. PubMed ID: 38550492
[TBL] [Abstract][Full Text] [Related]
3. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
[TBL] [Abstract][Full Text] [Related]
4. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
[TBL] [Abstract][Full Text] [Related]
5. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
[TBL] [Abstract][Full Text] [Related]
6. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
[TBL] [Abstract][Full Text] [Related]
8. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report.
Li X; Wu W; Zeng Y; Wu W; Hou C; Zhu H; Liao Y; Tian Y; Chen Z; Peng B; Chen WX
Front Immunol; 2023; 14():1257955. PubMed ID: 37915570
[TBL] [Abstract][Full Text] [Related]
9. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
Paton DM
Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218
[TBL] [Abstract][Full Text] [Related]
10. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.
Meher BR; Mohanty RR; Dash A
Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672
[TBL] [Abstract][Full Text] [Related]
11. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
[TBL] [Abstract][Full Text] [Related]
12. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders.
Gao Y; Zhang B; Yang J
Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
[TBL] [Abstract][Full Text] [Related]
14. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Duchow A; Bellmann-Strobl J
Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
[TBL] [Abstract][Full Text] [Related]
15. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder].
Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559
[TBL] [Abstract][Full Text] [Related]
16. Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.
Uzawa A; Mori M; Iwai Y; Masuda H; Kuwabara S
Intern Med; 2022 Sep; 61(18):2785-2787. PubMed ID: 35135926
[TBL] [Abstract][Full Text] [Related]
17. Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab.
Fujita R; Aratake Y; Nakata K; Fujii C; Kondo T
Intern Med; 2023 Nov; 62(22):3317-3320. PubMed ID: 37032080
[TBL] [Abstract][Full Text] [Related]
18. Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.
Pestchanker C; Diaconchuk M; Lopez P; Montaño MR; Romero W; Zalazar G; Carnero Contentti E
Mult Scler; 2023 Jan; 29(1):150-153. PubMed ID: 36437566
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
Lotan I; McGowan R; Levy M
Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
[TBL] [Abstract][Full Text] [Related]
20. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]